We investigated the effect of three Plk1 inhibitors (BI-2536, GSK-461363 and Rigosertib) on Plk1 expression in the chronic myelogenous cell line (CML) K562. This evidence concerns the gene PLK1 and chronic myelogenous leukemia, BCR-ABL1 positive.